![img](/resources/assets/images/affiliate_logo1.png)
![img](/resources/assets/images/affiliate_logo1_mo.png)
Artiva Biotherapeutics develops and brings NK cell therapy products developed at GC Cell to the global market
![img](/resources/assets/images/affiliate_img1.jpg)
Dedicated to revolutionizing cancer and autoimmune treatment, Artiva’s mission is to deliver cutting-edge, off-the-shelf, allogeneic NK cell-based therapies to patients. Leveraging its strategic partnership with GC Cell, Artiva develops therapies based on Manufacturing-First approach that are not only highly effective but also safe and accessible to cancer patients. At the forefront of Artiva's pipeline is AB-101, an ADCC enhancer NK-cell therapy designed for synergistic use with monoclonal antibodies or innate-cell engagers.
Beyond this, Artiva envisions advancing the field further by developing and commercializing CAR-NK technology developed at GC Cell. With a commitment to advancing the frontiers of biotechnology, Artiva Biotherapeutics and GC Cell stands poised to redefine the landscape of cancer therapeutics, offering hope and innovation to patients worldwide.